1. DSpace at My University
  2. E-Journal
  3. Teknologi Bank Darah
  4. Jurnal Internasional
  5. Journal of Microbiology, Immunology and Infection
  6. Vol. 55 No. 1 (2022)
Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9146
Title: Efficacy and safety of anti-interleukin-5 therapy in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized, controlled trials
Authors: Lan, Shao-Huan
Lai, Chih-Cheng
Chang, Shen-Peng
Hsu, Chun-Chun
Chen, Cheng-Hsin
Wang, Ya-Hui
Keywords: COPD;
Anti-IL-5;
Mepolizumab;
Benralizumab;
Eosinophil
Issue Date: 1-Feb-2022
Publisher: Elsevier Taiwan LLC
Abstract: Abstract Background: Anti-interleukin-5 (IL-5) therapy has been proposed as a novel treatment option for patients with chronic obstructive pulmonary disease (COPD). However, its efficacy for preventing COPD exacerbation remains unclear. Methods: A literature review was conducted to August 26th 2019. Only randomized controlled trials (RCTs) that investigated the clinical efficacy and adverse effects of anti-IL-5 therapy were included in the meta-analysis. The primary outcome was the risk of COPD exacerbation.
URI: http://localhost:8080/xmlui/handle/123456789/9146
ISSN: 1684-1182
Appears in Collections:Vol. 55 No. 1 (2022)

Files in This Item:
File Description SizeFormat 
26-35.pdf2.86 MBAdobe PDFView/Open
Show full item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.